At the beginning of September, Jiudian Pharmaceutical's Indobufen Tablets were approved for marketing by NMPA and were deemed to have passed the generic drug quality and efficacy consistency evaluation (Category 3 chemical drugs), bringing new treatment options for patients with cardiovascular diseases.

As a new generation of non-steroidal potent antiplatelet aggregation drugs, indobufen tablets are mainly used to treat ischemic cardiovascular disease, ischemic cerebrovascular disease, venous thrombosis and other diseases caused by arteriosclerosis. They can also be used to prevent thrombosis during hemodialysis. Its mechanism of action is to selectively act on platelets in the circulatory system, inhibit the excessive release of platelet factors, and then play the role of antiplatelet aggregation, so that abnormal platelet function can be restored without changing plasma parameters or damaging platelet function. Indobufen has low side effects and adverse reactions, and is the first choice for conservative treatment of senile peripheral vascular disease.

Compared with similar drugs, the antithrombotic effect of indobufen tablets is 2 to 5 times that of aspirin and clopidogrel, while the adverse reactions are only about 1/10 of aspirin and clopidogrel. Compared with aspirin, indobufen has the advantages of less damage to the gastric mucosa, low bleeding risk, and antiplatelet effect that can disappear within 24 hours after discontinuation of the drug. It is more suitable for the treatment of ischemic cardiovascular lesions caused by arteriosclerosis and patients with aspirin intolerance such as gastrointestinal bleeding or peptic ulcer history. In the treatment of acute mild ischemic stroke, indobufen is as effective as aspirin, but has fewer side effects and higher safety. In addition, indobufen can be used as a common alternative drug for patients with aspirin allergy or intolerance and aspirin resistance.

In 2017, indobufen was included in the national medical insurance catalog, and in 2018 it was included in the national basic drug catalog. According to the data of Minnet, among the TOP20 antithrombotic drugs in public hospitals in key provinces and cities in 2023, the sales of indobufen tablets increased by 34.48% year-on-year, successfully ranking among the top 3 domestic antithrombotic oral preparations.

So far, Jiudian Pharmaceutical has as many as 28 varieties that have passed the generic drug quality and efficacy consistency evaluation. The drug registration certificate for Indobufen Tablets has not only injected new vitality into the company's development, but also laid a solid foundation for its continued development and growth in the future. It will also provide patients with safer, more effective, and high-quality drug options, and contribute to the development of the medical industry!